Cargando…
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
BACKGROUND: Glucagon‐like peptide‐1 receptor agonists may be a treatment option in patients with non‐alcoholic fatty liver disease (NAFLD). AIMS: To investigate the effects of semaglutide on liver stiffness and liver fat in subjects with NAFLD using non‐invasive magnetic resonance imaging (MRI) meth...
Autores principales: | Flint, Anne, Andersen, Grit, Hockings, Paul, Johansson, Lars, Morsing, Anni, Sundby Palle, Mads, Vogl, Thomas, Loomba, Rohit, Plum‐Mörschel, Leona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292692/ https://www.ncbi.nlm.nih.gov/pubmed/34570916 http://dx.doi.org/10.1111/apt.16608 |
Ejemplares similares
-
Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data
por: Andersen, Grit, et al.
Publicado: (2020) -
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
por: Nakajima, Atsushi, et al.
Publicado: (2021) -
Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis
por: Safadi, Rifaat, et al.
Publicado: (2021) -
Randomised clinical trial: a leucine‐metformin‐sildenafil combination (NS‐0200) vs placebo in patients with non‐alcoholic fatty liver disease
por: Chalasani, N., et al.
Publicado: (2018) -
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease
por: Shiffman, Mitchell, et al.
Publicado: (2018)